Stock ULTI ULTIMOVACS ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ultimovacs ASA

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-06-20 EDT 		5-day change 1st Jan Change
7.8 NOK -4.99% Intraday chart for Ultimovacs ASA -6.25% -93.65%
06-11 Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma CI
05-07 Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,092 2,558 3,860 3,784 4,225 268.4 - -
Enterprise Value (EV) 1 692.5 2,117 3,288 3,364 3,962 -65.13 -18.63 -89.63
P/E ratio -17.9 x -21.2 x -22.1 x -22.4 x -22.3 x -3.25 x -7.21 x -19.5 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - 3.08 x -
EV / Revenue - - - - - - -0.21 x -
EV / EBITDA -10.8 x -17.4 x -20.4 x -18.6 x -18.6 x 0.43 x 0.25 x 0.81 x
EV / FCF -11 x -19.5 x -26.1 x -20 x -20.9 x 0.34 x 0.23 x 0.81 x
FCF Yield -9.12% -5.13% -3.83% -4.99% -4.79% 296% 429% 123%
Price to Book 2.46 x 5.24 x 6.51 x 8.42 x 15.1 x 2.04 x 2.29 x -
Nbr of stocks (in thousands) 27,860 31,974 34,222 34,396 34,406 34,406 - -
Reference price 2 39.20 80.00 112.8 110.0 122.8 7.800 7.800 7.800
Announcement Date 20-02-14 21-02-17 22-02-17 23-02-16 24-02-14 - - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 87 -
EBITDA 1 -64.15 -121.4 -161.1 -181 -213 -152.5 -73.5 -110
EBIT 1 -66.22 -124.1 -163.8 -183.6 -215.7 -154 -75 -110
Operating Margin - - - - - - -86.21% -
Earnings before Tax (EBT) 1 -61.17 -120.6 -164.7 -167.8 -189.2 -146.5 -72.04 -110
Net income 1 -61.17 -120.6 -164.7 -167.8 -189.2 -146.5 -72.04 -110
Net margin - - - - - - -82.8% -
EPS 2 -2.195 -3.770 -5.100 -4.900 -5.500 -2.402 -1.081 -0.4000
Free Cash Flow 1 -63.16 -108.5 -125.9 -167.9 -189.9 -193 -80 -110
FCF margin - - - - - - -91.95% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-02-14 21-02-17 22-02-17 23-02-16 24-02-14 - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 400 441 572 420 263 334 287 358
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -63.2 -109 -126 -168 -190 -193 -80 -110
ROE (net income / shareholders' equity) -20.2% -25.8% -30.5% -32.2% -51.9% -52.6% -32.8% -23%
ROA (Net income/ Total Assets) -18.3% -23.9% -27.6% - -44.1% -53.6% -32.5% -
Assets 1 334 503.9 596.3 - 429.4 273.4 221.6 -
Book Value Per Share 2 16.00 15.30 17.30 13.10 8.120 3.820 3.410 -
Cash Flow per Share - - - - - - - -
Capex - - 0.09 0.2 0.03 - - -
Capex / Sales - - - - - - - -
Announcement Date 20-02-14 21-02-17 22-02-17 23-02-16 24-02-14 - - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.8 NOK
Average target price
6.5 NOK
Spread / Average Target
-16.67%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ULTIMOVACS ASA Stock Ultimovacs ASA
-93.65% 25.46M
MODERNA, INC. Stock Moderna, Inc.
+35.14% 51.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.43% 39.03B
LONZA GROUP AG Stock Lonza Group AG
+35.88% 38.91B
CELLTRION, INC. Stock Celltrion, Inc.
-10.62% 26.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.63% 26.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-17.77% 19.91B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+40.52% 13.71B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.70% 12.38B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.41% 11.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ULTI Stock
  4. Financials Ultimovacs ASA